Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy

Ashish Manne; Yonghua Bao; Ankur Sheel; Amir Sara; Upender Manne; Kannan Thanikachalam; Kai He; Ashwini Kumar Esnakula; Ravi Kumar Paluri; Anup Kasi; Anne M Noonan; Arjun Mittra; John Hays; Sameek Roychowdhury; Pannaga Malalur; Shafia Rahman; Ning Jin; Jordan M Cloyd; Susan Tsai; Aslam Ejaz; Deepak Sherpally; Sravan Jeepalyam; Raj Shah; Mary Dillhoff; Lianbo Yu; Wancai Yang

doi:10.20944/preprints202409.0945.v1

How to cite: Manne, A.; Bao, Y.; Sheel, A.; Sara, A.; Manne, U.; Thanikachalam, K.; He, K.; Esnakula, A. K.; Paluri, R. K.; Kasi, A.; Noonan, A. M.; Mittra, A.; Hays, J.; Roychowdhury, S.; Malalur, P.; Rahman, S.; Jin, N.; Cloyd, J. M.; Tsai, S.; Ejaz, A.; Sherpally, D.; Jeepalyam, S.; Shah, R.; Dillhoff, M.; Yu, L.; Yang, W. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy. Preprints 2024, 2024090945. https://doi.org/10.20944/preprints202409.0945.v1 Manne, A.; Bao, Y.; Sheel, A.; Sara, A.; Manne, U.; Thanikachalam, K.; He, K.; Esnakula, A. K.; Paluri, R. K.; Kasi, A.; Noonan, A. M.; Mittra, A.; Hays, J.; Roychowdhury, S.; Malalur, P.; Rahman, S.; Jin, N.; Cloyd, J. M.; Tsai, S.; Ejaz, A.; Sherpally, D.; Jeepalyam, S.; Shah, R.; Dillhoff, M.; Yu, L.; Yang, W. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy. Preprints 2024, 2024090945. https://doi.org/10.20944/preprints202409.0945.v1

Abstract

Background: We explored the potential value of serum MUC5AC (sMUC5AC) as a biomarker to guide perioperative management of early-stage pancreatic ductal adenocarcinoma (PDA) patients receiving neoadjuvant therapy (NAT). Methods: We performed enzyme-linked immunoassays using a human MUC5AC kit (NBP2-76703) in serum samples obtained from The Ohio State Uni-versity biorepository (between January 2010 and June 2021). Univariate (UV) and multivariate (MV) Cox regression models were used to quantify progression-free survival (PFS); clinical and pathological variables were adjusted in the MV models. UV logistic regression analysis was utilized to examine the association of sMUC5AC with pathological features and survival. Results: Overall, 23 samples (19 FOLFIRINOX, 3 gemcitabine/nab-paclitaxel, 1 FOLFOX) were available for analysis. The median age was 66 years, and 52% were females. sMUC5AC was associated with a) treatment response, margin status, and residual disease (R0 vs. R1/R2) (all P

Keywords

Subject

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Not displayed online.

Please leave your comment to this article below.

Mathematical equations can be typed in either LaTeX formats \\[ ... \\] or $$ ... $$, or MathML format <math> ... </math>. Try the LaTeX or MathML example.

Type equation:

Preview:

Copy equation into message below

Close menu

Please click a symbol to insert it into the message box below:

Please enter the link here:

Optionally, you can enter text that should appear as linked text:

Copy link into message below

Please enter or paste the URL to the image here (please only use links to jpg/jpeg, png and gif images):

Copy image into message below

Type author name or keywords to filter the list of references in this group (you can add a new citation under Bibliography):

No existing citations in Discussion Group

Wikify editor is a simple editor for wiki-style mark-up. It was written by MDPI for Sciforum in 2014. The rendering of the mark-up is based on Wiky.php with some tweaks. Rendering of mathematical equations is done with MathJax. Please send us a message for support or for reporting bugs.

Please declare any conflicts of interest you may have with this paper, financial or otherwise.

I do not have a conflict of interest

I would like to declare a conflict of interest

Display my name on the website

Captcha

Renew

I accept the following conditions:

Comments must follow the standards of professional discourse and should focus on the scientific content of the article. Insulting or offensive language, personal attacks and off-topic remarks will not be permitted. Comments must be written in English. Preprints reserves the right to remove comments without notice. Readers who post comments are obliged to declare any competing interests, financial or otherwise.

Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy

Abstract

Keywords

Subject

Comments (0)